Trial Profile
A Phase III, Open Label, Randomized Trial of Ofatumumab Added to Fludarabine-Cyclophosphamide vs. Fludarabine-Cyclophosphamide Combination in Subjects With Relapsed Chronic Lymphocytic Leukemia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs Ofatumumab (Primary) ; Cyclophosphamide; Fludarabine
- Indications Chronic lymphocytic leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms COMPLEMENT 2
- Sponsors GlaxoSmithKline; GSK; Novartis
- 02 Jul 2019 Ther trial is completed at Romania (End Date: 25 Oct 2017), as per European Clinical Trials Database record.
- 04 Dec 2018 Results evaluating 5-year follow-up of overall survival (OS) and safety profile of the drugs presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
- 13 Dec 2017 Status changed from active, no longer recruiting to completed.